08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Jennerex Biotherapeutics, Transgene deal

SillaJen Inc. (Busan, South Korea), which acquired Jennerex in 2014, and Transgene amended a 2010 deal in which Jennerex granted Transgene exclusive rights to develop and commercialize Pexa-Vec in Europe, the Commonwealth of Independent...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Pexastimogene devacirepvec: Additional Phase Ib data

Additional data from an open-label, dose-escalation, Korean Phase Ib trial in 15 mCRC patients who failed previous treatment with standard chemotherapy showed that 1x10 6, 1x10 7 and 3x10 7 pfu/kg IV Pexa-Vec once every...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Tobira management update

Tobira Therapeutics Inc., San Francisco, Calif.   Business: Infectious   Hired: Chairman Laurent Fischer as CEO, formerly chairman and CEO of Jennerex Biotherapeutics Inc., which SillaJen Inc. acquired; he replaces Andrew Hindman, who resigned; and...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Jennerex Biotherapeutics, SillaJen deal

CRO SillaJen completed its acquisition of cancer company Jennerex for up to $150 million in cash in an undisclosed upfront payment, plus milestones. By the end of 1Q15, SillaJen plans to begin a Phase III...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Jennerex Biotherapeutics, SillaJen deal

CRO SillaJen is acquiring cancer company Jennerex for up to $150 million in cash in an undisclosed upfront payment, plus milestones. SillaJen has provided Jennerex with trial support services since 2007 and owns about 25%...
01:10 , Nov 27, 2013 |  BC Extra  |  Company News

SillaJen acquiring cancer company Jennerex

CRO SillaJen Inc. (Busan, South Korea) is acquiring cancer company Jennerex Biotherapeutics Inc. (San Francisco, Calif.) for up to $150 million in cash in an undisclosed upfront payment, plus milestones. SillaJen has provided Jennerex with...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Clinical News

Pexa-Vec pexastimogene devacirepvec: Phase IIb discontinued

Transgene stopped the open-label, international Phase IIb TRAVERSE trial after data from 80 patients with advanced HCC who have failed sorafenib showed that Pexa-Vec plus best supportive care (BSC) missed the primary endpoint of improving...
00:05 , Sep 5, 2013 |  BC Extra  |  Clinical News

Transgene falls on Pexa-Vec miss in second-line HCC

Transgene S.A. (Euronext:TNG) fell EUR 1.36 (13%) to EUR 8.90 on Wednesday after it said data from 80 patients showed Pexa-Vec ( JX-594) as second-line treatment missed the primary endpoint in the Phase IIb TRAVERSE...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Aduro BioTech management update

Aduro BioTech Inc., Berkeley, Calif.   Business: Cancer, Infectious   Hired: Gregory Schafer as COO, formerly COO of Jennerex Biotherapeutics Inc.   ...